It is an important point but we cant at the moment say anything about that, he said. The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. That rose to more than 85% after the second dose. The numbers were very small and there was uncertainty over their significance, said the researchers.
it was not set up to look at any differences between the two. The Pfizer/ BioNTech was available first so there is more data, but the Oxida/AstraZeneca was mostly used in the older age group. NOVICISCO.A  MANYOlde England.
( z0 multi-sentence :snt ( z1 set-up :ARG1 ( z2 it ) :ARG2 ( z3 look :ARG0 z2 :ARG1 ( z4 differ :ARG1 ( z5 thing :quant 2 ) :mod ( z6 any ) ) ) :polarity - ) :snt ( z7 cause :ARG0 ( z8 available :ARG1-of ( z9 contrast :ARG2 ( z10 use :ARG1 ( z11 slash :op ( z12 product :name ( z13 name :op "Oxida" ) ) :op ( z14 company :name ( z15 name :op "AstraZeneca" ) ) ) :ARG2 ( z16 group :mod ( z17 age :ARG1-of ( z18 have-degree :ARG2 ( z19 old ) :ARG3 ( z20 more ) ) ) ) :frequency ( z21 most ) ) ) :ARG2 ( z22 slash :op ( z23 company :name ( z24 name :op "Pfizer" ) ) :op ( z25 company :name ( z26 name :op "BioNTech" ) ) ) :ord ( z27 ordinal-entity :value 1 ) ) :ARG1 ( z28 data :quant ( z29 more ) ) ) :snt ( z30 country :name ( z31 name :op "NOVICISCO" :op "England" ) :quant ( z32 many ) ) )
(z0 / multi-sentence
    :snt1 (z1 / set-up-03
              :ARG1 (z2 / it)
              :ARG2 (z3 / look-01
                        :ARG0 z2
                        :ARG1 (z4 / differ-02
                                  :ARG1 (z5 / thing
                                            :quant 2)
                                  :mod (z6 / any)))
              :polarity -)
    :snt2 (z7 / cause-01
              :ARG0 (z8 / available-02
                        :ARG1-of (z9 / contrast-01
                                     :ARG2 (z10 / use-01
                                                :ARG1 (z11 / slash
                                                           :op1 (z12 / product
                                                                     :name (z13 / name
                                                                                :op1 "Oxida"))
                                                           :op2 (z14 / company
                                                                     :name (z15 / name
                                                                                :op1 "AstraZeneca")))
                                                :ARG2 (z16 / group
                                                           :mod (z17 / age
                                                                     :ARG1-of (z18 / have-degree-91
                                                                                   :ARG2 (z19 / old)
                                                                                   :ARG3 (z20 / more))))
                                                :frequency (z21 / most)))
                        :ARG2 (z22 / slash
                                   :op1 (z23 / company
                                             :name (z24 / name
                                                        :op1 "Pfizer"))
                                   :op2 (z25 / company
                                             :name (z26 / name
                                                        :op1 "BioNTech")))
                        :ord (z27 / ordinal-entity
                                  :value 1))
              :ARG1 (z28 / data
                         :quant (z29 / more)))
    :snt3 (z30 / country
               :name (z31 / name
                          :op1 "NOVICISCO"
                          :op1 "England")
               :quant (z32 / many)))
it was not set up to look at any differences between the two . The Pfizer / BioNTech was available first so there is more data , but the Oxida / AstraZeneca was mostly used in the older age group . NOVICISCO . A MANYOlde England .
z1 :polarity 0
z1 :ARG1 z2
z1 :ARG2 z3
z3 :ARG0 z2
z4 :mod z6
z3 :ARG1 z4
z4 :ARG1 z5
z5 :quant 2
z0 :snt1 z1
z23 :name z24
z24 :op1 8
z22 :op1 z23
z22 :op2 z25
z25 :name z26
z26 :op1 4
z8 :ARG2 z22
z8 :ord z27
z27 :value 1
z7 :ARG0 z8
z0 :snt2 z7
z28 :quant z29
z7 :ARG1 z28
z8 :ARG1-of z9
z13 :op1 7
z11 :op1 z12
z12 :name z13
z11 :op2 z14
z14 :name z15
z15 :op1 3
z10 :frequency z21
z10 :ARG1 z11
z9 :ARG2 z10
z18 :ARG2 z19
z18 :ARG3 z20
z17 :ARG1-of z18
z16 :mod z17
z10 :ARG2 z16
z31 :op1 6
z30 :quant z32
z30 :name z31
z0 :snt3 z30
z31 :op1 5